Novo Nordisk fell nearly 4% in pre-market trading to $70.87. On the news front, Novo Nordisk disclosed the complete data of two Phase III clinical trials of its new weight loss drug CagriSema, showing that the drug performed positively in terms of weight loss and improvement of metabolic indicators, but the incidence of gastrointestinal side effects was higher than that of the placebo group. This result is basically consistent with the previously announced interim data, but it failed to fully meet the expectations of the capital market. Novo Nordisk previously announced the details of a 68-week clinical study at the American Diabetes Association Annual Meeting held in Chicago. Overweight or obese non-diabetic patients treated with CagriSema lost an average of about 23% of their weight, and patients with type 2 diabetes and overweight lost 15.8%.